Accordingly, combined anti–PD‐L1/anti–CTLA‐4 therapy has been shown to be effective across multiple tumor types, as initially confirmed in advanced melanoma17, 18, 19 and also in NSCLC20 and renal cell carcinoma.21 Here, CTLA4 is linked to neoplasm.